Literature DB >> 28791398

PI3K/AKT signaling pathway activation in a rat model of migraine.

Yun-Yong Liu1, Zi-Yao Jiao2, Wei Li1, Qian Tian1.   

Abstract

The present study aimed to investigate phosphatidylinositol 4,5-bisphosphate 3‑kinase (PI3K)/protein kinase B (AKT) signaling pathway activation in a rat model of migraine. A total of 60 male Sprague‑Dawley rats were randomly divided into three groups: Blank control; suspension control; and migraine model. The model group was subcutaneously injected with a glyceryl trinitrate suspension, using an optimized Tassorelli method to establish a rat model of migraine. The activation status of the PI3K/AKT signaling pathway was assessed via measurement of the phosphorylated (p)‑AKT level. The level of serum 5‑hydroxytryptamine was detected using an ELISA. The mRNA and protein expression levels of PI3K and AKT, and protein levels of p‑AKT were detected by reverse transcription quantitative polymerase chain reaction and western blot analysis. Expression of the PI3K gene was significantly increased (P<0.01) 6‑24 h following the glyceryl trinitrate injection. There was no significant difference in the expression of AKT between any of the groups at any time. Expression of p‑AKT (S473) was significantly increased in the migraine model group (P<0.01) compared with the controls groups. Immunohistochemical analysis indicated that phosphatase and tensin homolog (PTEN) continuously decreased in the migraine model group during 1‑12 h, however this was only significant in the 12 h group. Levels of PTEN had increased again by 24 h. Glycogen synthase kinase (GSK)‑3β expression exhibited a similar expression pattern to PTEN. The results indicated that the PI3K/AKT signal pathway may be activated in the brain tissue of the rat migraine models. The inhibition of PTEN, which is an upstream modulator of the PI3K/AKT signaling pathway, may enhance the activation of phosphatidylinositol‑3,4,5‑triphosphate, thus inhibiting the expression of GSK-3β.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28791398     DOI: 10.3892/mmr.2017.7191

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  Network Pharmacology-Based Investigation on Therapeutic Mechanisms of the Angelica dahurica Radix and Ligusticum chuanxiong Rhizoma Herb Pair for Anti-Migraine Effect.

Authors:  Chu Duc Thanh; Chu Van Men; Hyung Min Kim; Jong Seong Kang
Journal:  Plants (Basel)       Date:  2022-08-24

2.  Artificial intelligence analysis to explore synchronize exercise, cobalamin, and magnesium as new actors to therapeutic of migraine symptoms: a randomized, placebo-controlled trial.

Authors:  Hanie Matin; Farzaneh Taghian; Ahmad Chitsaz
Journal:  Neurol Sci       Date:  2022-02-03       Impact factor: 3.307

3.  Shared Molecular Genetic Mechanisms Underlie Endometriosis and Migraine Comorbidity.

Authors:  Emmanuel O Adewuyi; Yadav Sapkota; Asa Auta; Kosuke Yoshihara; Mette Nyegaard; Lyn R Griffiths; Grant W Montgomery; Daniel I Chasman; Dale R Nyholt
Journal:  Genes (Basel)       Date:  2020-02-29       Impact factor: 4.096

4.  Identification of Constituents and Exploring the Mechanism for Toutongning Capsule in the Treatment of Migraine.

Authors:  Xia Du; Zhibiao Di; Yang Liu; Wenbing Zhi; Yuan Liu; Hong Zhang; Feng Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-01-15       Impact factor: 2.629

5.  Dopamine receptor D2 regulates GLUA1-containing AMPA receptor trafficking and central sensitization through the PI3K signaling pathway in a male rat model of chronic migraine.

Authors:  Wei Zhang; Ming Lei; Qianwen Wen; Dunke Zhang; Guangcheng Qin; Jiying Zhou; Lixue Chen
Journal:  J Headache Pain       Date:  2022-08-10       Impact factor: 8.588

6.  Differential Expression and Bioinformatic Analysis of the circRNA Expression in Migraine Patients.

Authors:  Jinghan Lin; Shanshan Shi; Qihui Chen; Yonghui Pan
Journal:  Biomed Res Int       Date:  2020-10-07       Impact factor: 3.411

7.  Involvement of 5-Hydroxytryptamine Receptor 2A in the Pathophysiology of Medication-Overuse Headache.

Authors:  Zhenyang Zheng; Xiaolei Shi; Yue Xiang; Aiwu Zhang; Yannan Fang
Journal:  J Pain Res       Date:  2021-02-16       Impact factor: 3.133

8.  Activation of microglial GLP-1R in the trigeminal nucleus caudalis suppresses central sensitization of chronic migraine after recurrent nitroglycerin stimulation.

Authors:  Feng Jing; Qian Zou; Yangyang Wang; Zhiyou Cai; Yong Tang
Journal:  J Headache Pain       Date:  2021-07-29       Impact factor: 7.277

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.